The Use of Multimodal Perineural Adjuvants in Pediatric Peripheral Nerve Blocks: Technique and Experiences

Background Postoperative pain management in pediatric population can be very challenging. How to prolong the duration of single-injection peripheral nerve blocks has been widely discussed. Multiple medications are under investigation to accomplish this, yet data specifically focused on their use in pediatric peripheral nerve blocks are limited. Methods Anesthetic electronic medical records were queried for any instances where adjuvant drug(s) were used in peripheral nerve blocks during a two-year period at a pediatric surgical specialty hospital. These included buprenorphine, clonidine, dexamethasone, and dexmedetomidine. Results Out of 1,845 blocks placed during the study period, 1,148 (62.2%) utilized perineural adjuvants. Buprenorphine as a sole agent was the most common choice (49.5%), followed by buprenorphine and dexmedetomidine combined (39.9%), dexmedetomidine alone (10.1%), and the rare combination of all three drugs, buprenorphine, dexmedetomidine, and dexamethasone (0.5%). The mean dose of buprenorphine given was 3.6 mcg/kg total, 2.8 mcg/kg/block. The mean dose of dexmedetomidine given was 0.9 mcg/kg total, 0.6 mcg/kg/block. The mean dose of dexamethasone utilized was 2 mg total, 1 mg/block. Conclusions This report examined one institution’s use of multimodal perineural adjuvants in over 1,000 pediatric peripheral nerve blocks. Buprenorphine was the agent most commonly used to prolong the single-injection peripheral nerve block. This highlights the need for future prospective trials evaluating efficacy and safety.